Evaluation of NAAGA efficacy in dry eye syndrome
OBJECTIVES: The aim of this study was to assess the efficacy of Naabak((R)) eyedrops in reducing inflammation in dry eye syndrome.
PATIENTS AND METHODS: This pilot, multicenter, randomized, double-blind, parallel study was carried out in adult patients suffering from moderate dry eye syndrome. Patients were treated for three months with preservative-free NAAGA (Naabak((R))) or with sodium chloride 0.9% without preservative (Larmabak(R)). They received the treatment four to six times a day during the 1(st) month and three to four times a day during the 2(nd) and 3(rd) months. At each visit (D28 and D84), clinical tests were performed as well as a biological evaluation of HLA-DR and MUC5AC expression on conjunctival imprints using flow cytometry.
RESULTS: After three months of treatment, the ocular surface symptoms and overall discomfort were improved in patients treated with Naabak(R) and in those treated with Larmabak(R) with no significant difference between the groups. Cytological impression showed a significant decrease in the expression of inflammatory markers, notably antigen HLA-DR, in the Naabak(R) group.
CONCLUSION: This study confirms the anti-inflammatory property of preservative-free NAAGA (Naabak(R)) in the context of dry eye syndrome with a similar clinical efficacy compared to sodium chloride solution (Larmabak(R)). Naabak(R) could present an additional advantage compared to artificial tears and could be indicated in the treatment of moderate inflammatory dry eye syndrome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Journal francais d'ophtalmologie - 32(2009), 9 vom: 01. Nov., Seite 613-20 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Evaluation de l'efficacité du NAAGA dans la sécheresse oculaire |
|---|
| Beteiligte Personen: |
Brignole-Baudouin, F [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.02.2010 Date Revised 25.11.2016 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jfo.2009.09.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM192279122 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM192279122 | ||
| 003 | DE-627 | ||
| 005 | 20231223192716.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2009 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.jfo.2009.09.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0641.xml |
| 035 | |a (DE-627)NLM192279122 | ||
| 035 | |a (NLM)19854539 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Brignole-Baudouin, F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of NAAGA efficacy in dry eye syndrome |
| 246 | 3 | 3 | |a Evaluation de l'efficacité du NAAGA dans la sécheresse oculaire |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.02.2010 | ||
| 500 | |a Date Revised 25.11.2016 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: The aim of this study was to assess the efficacy of Naabak((R)) eyedrops in reducing inflammation in dry eye syndrome | ||
| 520 | |a PATIENTS AND METHODS: This pilot, multicenter, randomized, double-blind, parallel study was carried out in adult patients suffering from moderate dry eye syndrome. Patients were treated for three months with preservative-free NAAGA (Naabak((R))) or with sodium chloride 0.9% without preservative (Larmabak(R)). They received the treatment four to six times a day during the 1(st) month and three to four times a day during the 2(nd) and 3(rd) months. At each visit (D28 and D84), clinical tests were performed as well as a biological evaluation of HLA-DR and MUC5AC expression on conjunctival imprints using flow cytometry | ||
| 520 | |a RESULTS: After three months of treatment, the ocular surface symptoms and overall discomfort were improved in patients treated with Naabak(R) and in those treated with Larmabak(R) with no significant difference between the groups. Cytological impression showed a significant decrease in the expression of inflammatory markers, notably antigen HLA-DR, in the Naabak(R) group | ||
| 520 | |a CONCLUSION: This study confirms the anti-inflammatory property of preservative-free NAAGA (Naabak(R)) in the context of dry eye syndrome with a similar clinical efficacy compared to sodium chloride solution (Larmabak(R)). Naabak(R) could present an additional advantage compared to artificial tears and could be indicated in the treatment of moderate inflammatory dry eye syndrome | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Anti-Allergic Agents |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Dipeptides |2 NLM | |
| 650 | 7 | |a HLA-DR Antigens |2 NLM | |
| 650 | 7 | |a MUC5AC protein, human |2 NLM | |
| 650 | 7 | |a Mucin 5AC |2 NLM | |
| 650 | 7 | |a Ophthalmic Solutions |2 NLM | |
| 650 | 7 | |a Preservatives, Pharmaceutical |2 NLM | |
| 650 | 7 | |a isospaglumic acid |2 NLM | |
| 650 | 7 | |a 1W8M12WXYL |2 NLM | |
| 700 | 1 | |a Robert, P-Y |e verfasserin |4 aut | |
| 700 | 1 | |a Creuzot-Garcher, C |e verfasserin |4 aut | |
| 700 | 1 | |a Olmiere, C |e verfasserin |4 aut | |
| 700 | 1 | |a Delval, L |e verfasserin |4 aut | |
| 700 | 1 | |a Baudouin, C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal francais d'ophtalmologie |d 1993 |g 32(2009), 9 vom: 01. Nov., Seite 613-20 |w (DE-627)NLM000357944 |x 1773-0597 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2009 |g number:9 |g day:01 |g month:11 |g pages:613-20 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jfo.2009.09.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2009 |e 9 |b 01 |c 11 |h 613-20 | ||